Skip to Main Content

Paper Details

Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension.
Eur Respir J
26
2022
C-reactive protein, IL-6, IL6R, IL6R variant, PAH, Tocilizumab, connective tissue disease, dysregulated, idiopathic/heritable disease, interleukin-6, patients, plasma interleukin-6, pulmonary arterial hypertension, rs7529229, tocilizumab
Author NameAffiliation
Amit AroraUniversity of Arizona
Stefan Gr??fUniversity of Cambridge
Jason H KarnesUniversity of Arizona
Rick A KittlesUniversity of Arizona
Florent SoubrierSorbonne Universites, INSERM
Richard C TrembathKing's College
  • 1 - 6

Datasets

Release 1.2